Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMABKHH)

Drug Name
ARO-APOC3 Drug Info
Indication
Disease Entry ICD 11 Status REF
Familial chylomicronemia syndrome 5C80 Phase 3 [1]
Hypertriglyceridemia 5C80.1 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMABKHH

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ApoC-III messenger RNA (APOC3 mRNA) TTXOZQ1 APOC3_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
ApoC-III messenger RNA (APOC3 mRNA) DTT APOC3 12.577 4.597 2.293 10.581
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Familial chylomicronemia syndrome
ICD Disease Classification 5C80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
ApoC-III messenger RNA (APOC3 mRNA) DTT APOC3 2.67E-01 0.1 0.59
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05089084) A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04720534) A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia. U.S.National Institutes of Health.
3 ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr Atheroscler Rep. 2021 Mar 10;23(5):20.